Zogenix, a pharmaceutical company, has reported positive data demonstrating the effectiveness and cardiovascular-related safety for ZX008 to treat seizures associated with Lennox Gastaut Syndrome (LGS).
The company also reported continued effectiveness and safety for patients with Dravet syndrome.
“These initial data indicate that ZX008 has the potential to be a safe and effective adjunctive treatment for this rare pediatric epilepsy condition,” said Lieven Lagae, lead investigator of the trial.
LGS is a type of epilepsy with multiple different types of seizures. Dravet syndrome is a rare genetic epileptic encephalopathy that afflicts infants. The data were presented at the American Epilepsy Society (AES) meeting in Houston.